by Denkstrom
All storiesmFLUSIVA: First mRNA Flu Vaccine Approved

mFLUSIVA: First mRNA Flu Vaccine Approved

The FDA approved mFLUSIVA by Moderna on August 5, 2026, the world's first flu vaccine based on mRNA technology. In the phase 3 study, it protected 26.6 percent better than conventional flu vaccines.

Every spring, WHO experts decide which flu strains the vaccine for the coming season should protect against. The prediction can be wrong, production takes months, and corrections are barely possible. On August 5, 2026, the FDA approved Moderna's mFLUSIVA, the world's first flu vaccine based on mRNA technology. The technology that proved itself with COVID-19 vaccines is now changing flu protection as well.

Why conventional flu vaccines can fall behind every year

Conventional flu vaccines are produced mostly in fertilized chicken eggs, a procedure from the 1940s. A production batch takes several months. Influenza viruses, however, constantly change and the vaccine must be tailored to the strains that will actually dominate the coming season. If the WHO prediction misses the mark, vaccine effectiveness drops dramatically.

In the US flu season of 2014/15, for example, the Centers for Disease Control and Prevention estimated total vaccine effectiveness at only 19 percent because the A/H3N2 strain used in the vaccine had drifted antigenically from the variants actually circulating. According to CDC data, the average effectiveness of conventional flu vaccines ranges from 40 to 60 percent, depending on how accurately the prediction hits the mark.

FLUENT: What 40,805 study participants across 11 countries show

mFLUSIVA was tested in the phase 3 FLUENT study: 40,805 adults aged 50 and older in 11 countries, with an approved standard-dose flu vaccine as the comparison arm. The relative effectiveness of mFLUSIVA compared to the standard vaccine was 26.6 percent according to the FDA (95 percent confidence interval: 16.7 to 35.4 percent). This means: mFLUSIVA prevented 26.6 percent more flu cases than the comparison vaccine.

Broken down by strain, the picture showed the following: Against A/H1N1, relative effectiveness was 29.6 percent; against B/Victoria, 29.1 percent. For A/H3N2, the strain with the greatest historical variability and most frequent prediction misses, mFLUSIVA achieved 22.2 percent relative effectiveness.

The FDA granted regular full approval for adults aged 50 to 64 years, based on effectiveness data from the FLUENT study. For adults aged 65 and older, who most frequently develop flu-related complications, the agency granted accelerated approval based on surrogate endpoints such as antibody levels. Moderna is required to submit additional effectiveness data for this age group in a post-approval study covering two flu seasons.

Comparison: What COVID proved for the mRNA platform

Until the end of 2020, no mRNA vaccine had ever been regulatory approved for broad population protection programs. COVID vaccines from BioNTech/Pfizer and Moderna changed that within one year: both showed initial effectiveness rates exceeding 90 percent against severe disease in phase 3 studies; the FDA granted first emergency authorizations in December 2020. Since regular full approval, both have been administered hundreds of millions of times.

Moderna had already obtained FDA approval in 2024 for mRESVIA, an mRNA vaccine against respiratory syncytial virus (RSV) for adults aged 60 and older. mFLUSIVA is the second non-COVID vaccine based on mRNA technology with US approval and the first against influenza.

For flu vaccines, the adaptation speed of mRNA technology is particularly relevant: an mRNA sequence can be updated within days to adapt to new viral variants once their genetic code is known. Classical egg production, by contrast, takes months and can barely be corrected on short notice. Moderna plans to have mFLUSIVA available for the 2026/27 flu season.

H3N2 and the 65+ study: What remains unproven

With the accelerated approval for older adults, the most important question remains open: how well does mFLUSIVA protect people aged 65 and older in a real flu season? This age group bears the bulk of flu-associated disease burden. Flu can lead to pneumonia, heart attacks, and other serious complications in older patients. The post-approval study that Moderna must submit will answer this question over two seasons.

The second open question concerns H3N2. This strain historically causes the most severe flu waves and has been most difficult to hit. mFLUSIVA's relative effectiveness of 22.2 percent against H3N2 is better than conventional vaccines in the worst seasons, but the value lies well below what was achieved against H1N1. Whether the mRNA approach proves durably superior will require several seasons to show. Until the post-approval study data become available, that will likely be 2028 or 2029.